HLA-DRA and nonpapillary renal cell carcinoma: Given that the expression level of PD-L1 can be used as a predictor of a patient’s sensitivity to ICI therapy, we examined PD-L1 protein expression in 146 ccRCC tissue samples and performed Pearson’s correlation analysis between HLA-DRA and PD-L1 expression.